Clinical Trial

Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males

Study acronym: RIGHT
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a prospective, single-center, two-arm Phase 1 safety and feasibility trial evaluating anti-estrogen therapy in men age 50 years and older with symptomatic unilateral inguinal hernias. Participants will be randomized to receive Fulvestrant 250 mg intramuscularly or anastrozole 1 mg orally for 6 months. The study will evaluate safety, tolerability, feasibility, hormone changes, hernia size, patient-reported outcomes, bone density, and imaging-based hernia classification.
Protocol Amendment History 5 changes
notable Primary completion pushed: 2028-06 -> 2028-07 2026-08-04
minor Completion pushed: 2028-06 -> 2028-07 2026-08-04
critical Recruitment opened 2026-06-27
notable Enrollment reduced: 75 -> 30 participants 2026-06-12
minor Trial arms changed: 3 -> 2 2026-06-12
Trial Details
NCT Number NCT07604272
Lead Sponsor Northwestern University
Conditions Inguinal Hernia Unilateral, Inguinal Hernia Bilateral, Inguinal Hernia Without Obstruction or Gangrene, Inguinal Hernia, Without Mention of Obstruction or Gangrene
Enrollment 30 participants
Start Date 2026-07-31
Primary Completion 2028-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-03